Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial

Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA)...

Scientists Synthesize Unique Family of Anti-Cancer Compounds

(PhysOrg.com) -- Yale University scientists have streamlined the process for synthesizing a family of compounds with the potential to kill cancer and other diseased cells, and have found that they represent a unique category of anti-cancer agents. Their discovery appears in this week`s online edition of the Journal of the American Chemical...

Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights

BELLEVILLE, ON, Feb. 12 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology driven Canadian biopharmaceutical company, today announced that it has met the obligations associated with two milestones under its licensing agreement with Endo Pharmaceuticals ( ENDP) for exclusive rights to develop and market Bioniche's proprietary product for non-muscle-invasive bladder cancer in North America. The achievement of these milestones triggers a total payment of...

Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval

Abbott's ARCHITECT human epididymis protein 4 (HE4) assay submitted for 510(k) clearance ABBOTT PARK, Ill., Feb. 8 /PRNewswire-FirstCall/ -- A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the United States. Abbott's ARCHITECT HE4 assay uses a simple blood test to help in monitoring for the recurrence or progression of epithelial ovarian cancer. If approved, this important immunoassay would be the first...

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo...

Magnetic nanoparticles show promise for combating human cancer

Scientists at Georgia Tech and the Ovarian Cancer Institute have further developed a potential new treatment against cancer that uses magnetic nanoparticles to attach to cancer cells, removing them from the body. The treatment, tested in mice in 2008, has now been tested using samples from human cancer...

FDA OKs Onyx’s blockbuster Ph III cancer trial

When Onyx bought out Proteolix last year for $276 million down and up to $575 million in milestones, both sides highlighted the starring role of the cancer drug carfilzomib in the deal. Emeryville, CA-based Onyx included a $170 million payday if the drug gets an accelerated approval. And the developer sees the therapy as a likely blockbuster able to earn the kind of big bucks that Nexavar is racking up. Today, Onyx saw its share price buoyed by its announcement that the FDA had signed off on a...

Abbott pays $25M upfront for Pierre Fabre cancer pact

Wooed by the prospects of one of Pierre Fabre's promising pre-clinical cancer programs, Abbott Laboratories has agreed to pay the French biotech $25 million upfront, two years of research expenses and an undisclosed slate of milestones to buy its way into a worldwide licensing pact. Abbott's R&D team was lured by the antibody's potential for targeting the cMet receptor. cMet protein plays a role in the progression of a range of solid tumors--including prostate, lung and gastric...

Engineers develop cancer-targeting nanoprobe sensors

Scientists at UC Berkeley have created smart nanoprobes that may one day be used in the battle against cancer to selectively seek out and destroy tumor cells, as well as report back on the mission's status. The research team created multi-functioning probes, which they have dubbed nanocorals. A small number of research teams around the world have been developing target-specific nanoprobes for the past 10 years in an effort to reduce — and perhaps eliminate — the toxic toll chemotherapy...

Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer

Monoclonal Antibody Adds Early-Stage Biologic to Abbott's Oncology Pipeline ABBOTT PARK, Ill. and CASTRES, France, Feb. 1 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer. cMet protein plays a role in the progression of...